Published Research

All publications, and conference or seminar presentations arising from research utilizing the SDRNT1BIO cohort are listed below.
SDRNT1BIO investigators/staff are highlighted in bold.

Published papers

Conference/Event presentations

  • Genome-wide aggregation of trans-effects from proteomic studies indicates a key role of immune checkpoints in type 1 diabetes. 
     Zhou X
     Oral presentation at Edinburgh Alliance for Complex Trait Genetics (e-ACTG) 20th annual meeting; Edinburgh, UK, 7th March 2025
  • Discovery of core genes for type 1 diabetes via genome-wide aggregation of trans-effects using proteomics studies. 
     Zhou X, Iakovliev A, McGurnaghan SJ, Spiliopoulou A, Colhoun HM, McKeigue PM.
     Poster presentation at America Society of Human Genetics Annual Meeting 2024; Denver, USA, 7th November 2024
  • Long term effect of C peptide on clinical outcomes in the Scottish Type 1 Bioresource cohort. 
     Mellor J, Blackbourn LAK, McGurnaghan SJ, McKeigue PM, Zaccai J, Guenther O, Cui N, Colhoun HM.
     Oral presentation at Immunology of Diabetes Society (IDS) Annual Conference 2024; Bruges, Belgium, 6th November 2024
  • Discovery of core genes for type 1 diabetes via genome-wide aggregation of trans-effects using proteomics studies. 
     Zhou X, Iakovliev A, McGurnaghan SJ, Spiliopoulou A, Colhoun HM, McKeigue PM.
     Poster presentation at Immunology of Diabetes Society (IDS) Annual Conference 2024; Bruges, Belgium, 5th November 2024
  • Discovery of core genes for type 1 diabetes via genome-wide aggregation of trans-effects using proteomics studies. 
     Zhou X, Iakovliev A, McGurnaghan SJ, Spiliopoulou A, Colhoun HM, McKeigue PM.
     Poster presentation at Edinburgh Next Generation of Genomics Symposium (EnGoGS); Edinburgh, Scotland, 1st October 2024
  • Discovery of core genes for type 1 diabetes via genome-wide aggregation of trans-effects using UK Biobank proteomics study.
     Iakovliev A.
     Oral presentation at European Society for Human Genetics annual conference; Berlin, Germany, 2nd June 2024.
  • Identifying potential targets of therapy for preventing type 1 diabetes using genetics.
     Colhoun HM.
     Online presentation to Diabetes UK- part of Knowing Diabetes programme; 21st March 2024
  • Misclassification of diabetes type among those with a clinical label of type 1 diabetes: A study in the Scottish Diabetes Research Network Type 1 Bioresource (SDRNT1BIO).
     Colhoun HM.
    Oral presentation at event- Getting the Diabetes Diagnosis Right: Type 1, Monogenic or Other; Dunblane, Scotland, 26th May 2023.
  • Effect of genetic variants in FUT2 gene on risk of type 1 diabetes is explained by effects on plasma levels of NECTIN-2, C-C MOTIF CHEMOKINE 25 and C-C MOTIF CHEMOKINE 15.
     Iakovliev A, Spiliopoulou A, Colombo M, McGurnaghan SJ, Colhoun HM, McKeigue PM.
     Poster presentation at Diabetes UK Professional Conference; Liverpool, UK, 26-28 April 2023.
  • Trans-eQTL effects on risk of type 1 diabetes: a test of the sparse effector (omnigenic) hypothesis of complex trait genetics.
     Iakovliev A.
     Oral presentation at 17th meeting of the Edinburgh Alliance for Complex Trait Genetics; Edinburgh, UK, 8th March 2023.
  • A test of the sparse effector (omnigenic) hypothesis in autoimmune diseases: case study of T1D and SLE.
     Iakovliev A.
     Oral presentation (Seminar) at Pfizer - Universidad de Granada - Junta de Andalucía Centre for Genomics and Oncological Research (GENYO); Granada, Spain, February 2023.
  • Genetic Determinants of Diabetic Retinopathy in People with Type 1 Diabetes
     McGurnaghan SJ, Spiliopoulou A, Hatam S, Blackbourn LAK, Palmer CNA, McKeigue PM, Colhoun HM.
     Poster presentation at European Association for the Study of Diabetes virtual conference, 22-25 September 2020.
  • Genetic determinants of diabetic retinopathy in people with Type 1 Diabetes
     McGurnaghan SJ, Spiliopoulou A, Hatam S, Blackbourn LAK, Palmer CNA, McKeigue PM, Colhoun HM.
     Oral presentation at European Association for the Study of Diabetes virtual conference, 22-25 September 2020.
  • Antibody persistence is common in long standing type 1 diabetes
    McGurnaghan SJ, McDonald TJ, Blackbourn LAK, Caparrotta TM, McKeigue PM, Colhoun HM on behalf of the SDRNT1BIO Investigators.
     Poster presentation at European Association for the Study of Diabetes conference; Barcelona, Spain, 16-20 September 2019
  • Genetic determinants of estimated glomerular filtration rate (eGFR) in Type 1 Diabetes
     McGurnaghan SJ, Spiliopoulou A, Blackbourn LAK, McKeigue PM, Colhoun HM on behalf of the SDRNT1BIO Investigators.
     Poster presentation at American Diabetes Association meeting; San Francisco, USA, 7-11 June 2019
  • Use of C-peptide and autoantibodies in individuals clinically labelled as Type 1 to identify those likely to have Type 2 Diabetes
     McGurnaghan SJ, Ochs A, McKeigue PM, Colhoun HM on behalf of the SDRNT1BIO Investigators.
     Poster presentation at Diabetes UK Professional Conference; Liverpool, UK, 6-8 March 2019
  • C-peptide Persistence in People with Type 1 Diabetes: Predictors and Consequences
     McKeigue PM, Jeyam A, McGurnaghan SJ, Wulanagish W, Ochs A, Colombo M, Colhoun HM on behalf of SDRNT1BIO investigators.
     Oral plenary at the Immunology of Diabetes Society international congress; London, UK, October 2018.
  • Genetic determinants of type 1 diabetes
    Spiliopoulou A, McGurnaghan SJ on behalf of SDRNT1BIO investigators.
     Oral presentation at European Association for the Study of Diabetes; Berlin, Germany, 1-5 October 2018
  • The association between C-peptide levels and the transition to referable retinopathy in patients with Type 1 Diabetes
     Ochs A, McGurnaghan SJ, Blackbourn LAK, McKeigue PM, Colhoun HM on behalf of SDRNT1BIO investigators.
     Poster presentation at European Association for the Study of Diabetes; Berlin, Germany, 1-5 October 2018
  • Genotypic Associations with C-peptide Persistence in People with Type 1 Diabetes
     McKeigue PM, Spiliopoulou A, McGurnaghan S, Colombo M, McDonald TJ, Colhoun HM on behalf of the SDRNT1BIO investigators.
     Oral presentation at the American Diabetes Association Meeting; Orlando, USA, 22-26 June 2018
  • A Bayesian approach for the discovery of biomarkers of progression of nephropathy
     Colombo M, Valo E, McGurnaghan S, Dalton RN, Dunger D, Groop PH, McKeigue PM, Forsblom C, Colhoun HM on behalf of the SDRNT1BIO and FinnDIANE investigators.
     Oral presentation at the 31st Annual General Meeting of the European Diabetic Nephropathy Study Group; Groningen, Netherlands, 18-19 May 2018
  • Polymorphisms in ST3GAL4, ST6GAL1, PHIP, FUT8 are associated with variation within the serum N-glycome of Scottish type 1 diabetes patients
     Bermingham ML, Colombo M, McGurnaghan SJ, Blackbourn LAK, Vučković F, Pučić Baković M, Lauc G, Agakov FA, Agakov AS, Hayward C, Klaric L, McKeigue PM, Colhoun HM, SDRNT1BIO investigators.
     Poster presentation at European Association of the Study of Diabetes Annual Meeting; Lisbon, Portugal, 11-15 September 2017.
  • Biomarkers associated with progression of renal disease in type 1 diabetes
     Colombo M, Valo E, McGurnaghan SJ, Blackbourn LAK, Dalton RN, Dunger D, Groop PH, McKeigue PM, Forsblom C, Colhoun HM on behalf of the SDRNT1BIO and FinnDIANE Investigators.
     Poster presentation at European Association of the Study of Diabetes Annual Meeting; Lisbon, Portugal, 11-15 September 2017.
  • Contemporary Rates and Predictors of Renal Disease Progression in Type 1 Diabetes
     Colombo M, McGurnaghan SJ, Bell S, Palmer CNA, MacKenzie F, Chalmers J, Collier A, Green F, Lindsay RS, Macrury S, McKnight JA, Patrick AW, Pearson DW, Petrie J, Thekkepat S, McKeigue PM, Colhoun HM on behalf of the SDRNT1BIO investigators.
     Poster presentation at the 77th American Diabetes Association Scientific meeting; San Diego, USA, 9-13 June 2017.
  • Biomarkers associated with progression of renal disease in type 1 diabetes
     Colombo M, Valo E, McGurnaghan SJ, Dalton RN, Dunger D, Groop PH, McKeigue PM, Forsblom C, Colhoun HM, on behalf of the SDRNT1BIO and FinnDIANE Investigators.
     Oral presentation at the 30th Annual General Meeting of the European Diabetic Nephropathy Study Group; Helsinki, Finland, 19-20 May 2017.
  • Associations of serum N-glycans with glycaemic control and albuminuria in type 1 diabetes
     Colombo M, Vuckovic F, Pucic-Bakovic M, Looker H, Agakov F, Lauc, G, McKeigue PM, Colhoun HM on behalf of the SDRNT1BIO investigators.
     Poster presentation at European Association of the Study of Diabetes Annual Meeting; Stockholm, Sweden, 14-18 September 2015
  • Patterns of Glucose and Diabetes Management among Scottish Diabetes Research Network Type 1 Diabetes Bioresource (SDRNT1BIO) participants
     Looker H, Livingstone S, McGurnaghan SJ, Collier A, Green F, Lindsay RS, MacRury S, McKnight JA, Milburn K, Palmer CAN, Patrick AW, Pearson DWM, Pearson ER, Petrie J, Thekkepat S, Walker J, Colhoun HM on behalf of the SDRNT1BIO investigators.
     Poster presentation at the Diabetes UK Professional Conference; London, UK, 11-13 March 2015

This article was published on